Product Description: Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].
Applications: Cancer-programmed cell death
Formula: C6H6N6O2
References: [1]Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10(12):1383-92./[2]Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4./[3]Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131.
CAS Number: 85622-93-1
Molecular Weight: 194.15
Compound Purity: 99.98
Research Area: Cancer
Solubility: DMSO : 20.83 mg/mL (ultrasonic)/H2O : 2.86 mg/mL (ultrasonic)
Target: Apoptosis;Autophagy;DNA Alkylator/Crosslinker
English
Deutsch
